Generalized arterial calcification of infancy

Lore & Background

GACI is caused by mutations in the ENPP1 gene in 75% of subjects or in the ABCC6 gene in 10% of patients; in some cases the cause is unknown. The condition results from an inactivating mutation leading to decreased inorganic pyrophosphate (PPi), a potent inhibitor of calcium deposition in the vessel wall. Symptoms are caused by calcification of large and medium-sized arteries, including the aorta, coronary arteries, and renal arteries. The critical period for affected babies is the first six months after birth, as calcium buildup can restrict blood flow and become life threatening.

Reader's Guide

GACI is significant as a model for understanding the role of inorganic pyrophosphate in vascular calcification and for demonstrating the potential of bisphosphonate therapy. Use of bisphosphonates, particularly etidronate, appears to significantly increase survival. Prenatal and postnatal treatment with low-dose, cyclical bisphosphonates has resulted in complete resolution of vascular calcifications in some cases. The disorder also highlights the importance of genetic testing for ENPP1 and ABCC6 mutations, which can guide preimplantation genetic diagnosis or chorionic villus sampling. Survival to adulthood has been reported, sometimes with persistent hypertension and cardiovascular sequelae, and spontaneous regression of arterial calcifications can occur.

Did You Know?

• GACI affects males and females equally and occurs in populations all across the world.
• The earliest detected manifestation of the disease is typically reported around 16–20 weeks gestation, not 14 weeks as sometimes claimed.

Genetic Architecture & Classification

GACI is an exceedingly rare inherited disorder transmitted in an autosomal recessive pattern, requiring a child to inherit two defective gene copies—one from each parent. The disease splits into two genetically defined subtypes. Type 1, present in roughly three-quarters of identified cases, arises from biallelic ENPP1 gene mutations and is termed ENPP1 Deficiency. Beyond vascular damage, these children face heightened risk of Autosomal Recessive Hypophosphatemic Rickets Type 2, which weakens bones, causes joint and bone pain, produces deformities like bowed legs or knocked knees, creates dental problems, triggers ligament calcification, and limits stature; proper treatment can, however, strengthen the skeleton and minimize side effects. Type 2, seen in about one-tenth of patients, results from ABCC6 gene mutations (ABCC6 Deficiency). As these children age, they may develop features resembling pseudoxanthoma elasticum, a condition compromising elastic tissue in the skin, eyes, cardiovascular system, and gastrointestinal tract. In a small subset of infants, neither gene harbors a detectable mutation, leaving the cause unresolved. The disorder affects males and females equally across all populations worldwide, with an estimated incidence near one in 391,000 births and a carrier rate of roughly one in 312.

Pathophysiology & Clinical Picture

The molecular trigger in GACI is an inactivating mutation—either in ENPP1 or ABCC6—that sharply reduces extracellular inorganic pyrophosphate (PPi). Because PPi is a powerful natural brake on calcium deposition in vessel walls, its absence unleashes unregulated mineralization within muscular arteries. The internal elastic lamina becomes diffusely calcified and eventually ruptures, triggering occlusive changes in the tunica intima, progressive stenosis, and a marked loss of arterial elasticity. Large and medium vessels are hit hardest, including the aorta, coronary arteries, and renal arteries. The clinical window is brutal: symptoms typically emerge at birth or within the first six months, and this period is considered critical because calcium keeps accumulating in artery walls and any restriction of blood flow can rapidly become life-threatening. Cardiac failure is the single most common clinical finding. Other presentations span a wide spectrum—severe hypertension, marked cyanosis, edema, reduced or absent peripheral pulses, refusal to feed, tachypnea, vomiting, abdominal distension, respiratory distress, joint calcifications, hearing loss, kidney failure, and gastrointestinal complications. Prenatal clues such as decreased fetal activity, hydrops fetalis, polyhydramnios, pericardial effusion, and a low biophysical profile may also appear. Tragically, many infants succumb to vaso-occlusive disease, particularly when coronary arteries are involved.

Diagnostic Approach & Imaging

Because GACI can masquerade as many other neonatal conditions, clinicians are urged to consider it whenever an infant or young child presents with unexplained hypertension, cardiac failure, or sudden death. Postnatal gray-scale and color Doppler echocardiography, along with sonographic examinations, enable noninvasive assessment of severity and monitoring of progression, while contrast-enhanced MR angiography with breath-hold and cardiac gating techniques can delineate the full extent of arterial involvement. Characteristic findings include a structurally normal heart with mild concentric ventricular hypertrophy, cardiomegaly, pulmonary plethora, and multiple intracardiac and vascular calcifications. The aortic annulus, ascending aorta, transverse arch, descending aorta, main pulmonary artery, and coronary arteries often appear echo-dense. Abdominal ultrasound may reveal hepatosplenomegaly, ascites, renal echogenicity, and diffuse calcification of the aorta, common iliac, splenic, and renal arteries, with peritoneal calcifications overlying the liver and intestine. Brain ultrasound can show dilated lateral ventricles, a poorly developed corpus callosum, and leukomalacia. Periarticular calcifications at the wrists, ears, shoulders, ankles, and hips are also documented. Hyperechogenicity of vessel walls, a history of polyhydramnios, or prior early neonatal deaths in the family should raise suspicion. DNA testing can ultimately confirm the responsible ENPP1 or ABCC6 mutation.

Prevention, Prognosis & Family Planning

For families carrying GACI mutations, reproductive planning options have become increasingly accessible. Genetic testing can identify the two pathogenic variants—either the pair of ENPP1 mutations (accounting for 75% of identified cases) or the ABCC6 mutations (10%)—one inherited from each parent. Once both variants are characterized, couples may pursue preimplantation genetic diagnosis (PGD) during assisted reproduction or chorionic villus sampling (CVS) during early pregnancy to determine whether the embryo or fetus is affected. Prenatal ultrasound at around week 20 of gestation can sometimes detect an echogenic intracardiac focus (EIF), a small bright spot in the fetal heart thought to represent early mineralization or calcium hydroxyapatite deposits in the myocardium, or intravascular calcifications particularly in the iliac and abdominal aorta. It is important to note that EIFs are found in roughly 3–5% of entirely normal pregnancies, so this finding alone is not diagnostic. Survival statistics for GACI vary greatly, and many affected infants lose their lives to vaso-occlusive disease, particularly of the coronary arteries. The disease affects males and females equally and has been documented in populations across the globe, with an estimated incidence of approximately one in 391,000 births and a carrier frequency near one in 312.